Login to Your Account

Naloxegol Phase III Win Muted by FDA's CV Stance

By Marie Powers
Staff Writer

Tuesday, November 13, 2012
The FDA threw a wrench into the fireworks for AstraZeneca plc and Nektar Therapeutics Inc. after the companies reported positive top-line findings from two Phase III studies and a safety extension trial of naloxegol (NKTR-118) in noncancer-related pain and opioid-induced constipation (OIC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription